Purpose: To describe the clinical signs of gelatinous drop-like corneal dystrophy (GDLD) in a consanguineous Colombian family and determine the underlying genetic cause.
G elatinous drop-like corneal dystrophy (GDLD; MIM 204870) was first described in Japanese patients in 1914. 1 It is a rare autosomal recessive disease with features consistent with bilateral corneal amyloidosis, leading to pain and severe loss of sight. 2, 3 The majority of reports are from Japan, where the prevalence is estimated to be 1:300,000 individuals. 4 The first case report from outside Japan was from the United States, where it was termed primary familial amyloidosis of the cornea. 5 In Latin America, clinical reports of GDLD cases have been described from Mexico, with 13 cases observed over a 44-year period, and a single case from Brazil. [6] [7] [8] The phenotype of GDLD can gradually develop over time. In the first decade, there may only be subepithelial lesions that are similar to band-shaped corneal degeneration, or multiple small grayish epithelial nodules that cause severe photophobia, tearing, and foreign body sensation. Over time, the nodules increase in number and coalesce to give a mulberry appearance. Finally, in the third decade, there is secondary stromal opacification and neovascularization with severe visual loss. [9] [10] [11] The histopathological features include subepithelial and anterior stromal amyloid material deposit with loss of the Bowman layer. The amyloid deposits stain with Congo red and show birefringence and dichroism under polarized light. 12 Physiologically, there is increased permeability of the epithelial cell junction. 13 Biallelic mutations in TACSTD2 (previously M1S1 or TROP2), located on chromosome 1p32 cause GDLD (MIM 137290). 14 TACSTD2 encodes tumor-associated calcium signal transducer 2 protein that, in association with claudins 1 and 7, functions as a transmembrane glycoprotein to maintain the corneal epithelial barrier. Loss of this barrier function is associated with accumulation of amyloid in the cornea. 15 The purpose of this study is to report the clinical features of a consanguineous family with GDLD from Colombia and establish the genetic cause of disease.
MATERIALS AND METHODS
All participants or their parents provided informed consent for this study. The research was approved by the Ethics Committee of the Medical Research Institute of the University of Antioquia and adhered to the tenets of the Declaration of Helsinki. A consanguineous family affected with GDLD was examined ( Fig. 1) . A family history and pedigree was constructed and a clinical ophthalmological examination was performed. A therapeutic superficial keratectomy was performed for 1 patient (individual II:10), and the material was processed for histology. A 10-mL peripheral venous blood sample was taken and DNA extracted (DNeasy; Qiagen).
The single coding exon of TACSTD2 was amplified by polymerase chain reaction (PCR) using KapaRobust polymerase (Kapa Biosystems) with primers F: 59-CCTGCAGACCATCC-CAGAC-39 and R: 59-CAGGAAGCGTGACTCACTTG-39. 14 PCR products were purified using a MultiScreen PCR m96 plate (Millipore) and bidirectionally Sanger sequenced. Sequences were aligned and compared with the reference sequence using DNAstar package software version 8.0.2 (Lasergene). Variants were annotated in accordance with Ensembl transcript ID ENST00000371225.
Two different bioinformatics tools were applied to predict the effect of amino acid substitution on TACSTD2 function: SIFT (v4.0.3; http://sift.jcvi.org/), 16 which uses sequence homology to make predictions, and PolyPhen-2 (v2.0.23; http://genetics.bwh.harvard.edu/pph2/), 17 which uses both sequence-based and structure-based predictive features. TACSTD2 variants were checked for their frequency in the Exome Aggregation Consortium database (ExAC; http://exac. broadinstitute.org/about), which includes exome data from 63,358 individuals of varying ethnicity (Table 1) .
RESULTS
The family consisted of consanguineous parents from Caldas in Colombia (Fig. 1) . The parents had a normal ophthalmic examination. The couple had 10 male children, of whom II:1 and II:2 were unavailable for evaluation but had no reported ophthalmic symptoms. Individuals II:6, II:7, and II:11 were clinically unaffected. A maternal uncle was reported to have died blind with opaque corneas of unknown etiology. The son of II:3 (III:1) had no ophthalmic symptoms. Patient II:5 had a well-differentiated rectal mucinous adenocarcinoma diagnosed at age 22 years, but no other extraocular phenotype was noted in any patient.
Clinical Findings
All affected individuals had photophobia, foreign body sensation, and blurred vision. There was a significant variation in the phenotype between affected individuals. The proband (II: 10) had photophobia and ocular discomfort since the first year of life. Corneal opacities were noted at 3 years of age, with a visual acuity of count fingers right eye and light perception left eye. By age 10, there were dense central corneal opacities with an irregular friable surface with peripheral superficial neovascularization ( Fig. 2A ). He had a left superficial keratotomy with an amniotic membrane onlay graft and temporal tarsorrhaphy. After 6 months, the Mutations were annotated according to Ensembl transcript ID ENST00000371225. Predictions of pathogenicity were scored using SIFT, with a score of likely pathogenicity from 1 to 0 based on sequence homology, and Polyphen2, with a score from 0 to 1 based on homology and structural features. The frequency of the mutation in the control population was determined using ExAC.
NP, not present (in database).
grey subepithelial band-shaped opacities without neovascularization, with late epithelial stain after instillation of fluorescein ( Fig. 2D, E ). In addition, 2 affected individuals (II:3 and II:8) also showed perilimbal deposits suggestive of amyloid material (Fig. 2F ).
Genetic Analysis of TACSTD2
Screening the TACSTD2 gene identified a single variant, c.551A.G, p.(Y184C) (rs190800473), which fully segregated with the disease in the family. All affected individuals were homozygous for the mutation, both unaffected parents (I:1 and I:2), 1 healthy sibling (II:7), and the son of affected individual II:3 (III:1) were heterozygous for the mutation. All remaining unaffected family members were homozygous wild-type (Fig. 1) .
The same mutation has previously been identified in a compound heterozygous state in an affected individual in combination with the Japanese founder mutation c.352C.T, p.(Q118X), and is therefore considered to be disease causing. 18 This is the first report of the mutation in the homozygous state. The TACSTD2 gene is present only in mammals, birds, and reptiles. The nonsynonymous variant, p.(Y184C), alters a highly conserved residue (see Figure, Supplemental Digital Content 2, http://links.lww.com/ICO/A422). Using SIFT and Polyphen2 prediction tools, the p.(Y184C) substitution is predicted to be Damaging (0) and Probably Damaging (0.994), respectively.
The variant was identified only once in the heterozygous state out of 107,098 alleles in the ExAC database; thus, this variant is extremely rare (MAF = 0.000009337). The ExAC data set combines exome-sequencing data from largescale sequencing projects worldwide; the single occurrence of the mutation was detected in an individual of Colombian origin sequenced as part of the 1000 Genomes Project. In total, 93 Colombian individuals were sequenced; therefore, the variant has an MAF of 0.53% in this specific population.
DISCUSSION
This is the first time, to our knowledge, that GDLD has been genetically solved in patients of Latin American origin ( Table 1 ). The causative homozygous TACSTD2 mutation identified in all affected family members has only previously been identified in the compound heterozygous state in a Chinese patient. 18 The identification of 5 affected individuals in this consanguineous family helps to define the phenotypic spectrum associated with the p.(Y184C) TACSTD2 mutation, which shows clinical variability between affected individuals. Two affected individuals (II:8 and II:9), aged 14 and 11 years, had a mild phenotype with an appearance similar to band-shaped keratopathy, characteristic of early GDLD. 11, 13 The remaining 3 affected family members (II:3, II:5, and II:10), aged 25, 23, and 10 years, had a more characteristic phenotype with a mulberry appearance and secondary stromal neovascularization of the cornea, associated with severe photophobia, discomfort, and blindness. These differences suggest that environmental or other genetic factors contribute to the phenotype. Because this family is consanguineous, affected individuals are likely to share an extended haplotype at the TACSTD2 locus so genetic variants in the shared genomic interval are unlikely to contribute to the observed phenotypic variability. Similarly, Tsujikawa et al 19 described a homozygous Q118X mutation in 4 Japanese families with inter-and intrafamilial phenotypic variability. Previous reports have indicated that the phenotypic variability for this dystrophy is because of age-related progression over time, as the nodular subepithelial amyloid deposits gradually increase in number and coalesce during the first and second decades of life, 3, 9, 10 and it remains possible that the milder phenotype observed in some individuals in this family could progress in the next few years or decades. Two affected individuals (II:3 and II:8) also showed perilimbal deposits suggestive of amyloid material, although confirmation would require a histopathological examination. 20 GDLD is normally associated with severe ocular morbidity and blindness. Visual rehabilitation is problematic, often requiring multiple surgical interventions, with a high rate of recurrence and continued visual decline. After superficial excision of affected material, lamellar or penetrating keratoplasty, temporary improvement can be achieved, but with recurrence at an average of 26 months. 21, 22 Individual II:10 had a superficial keratotomy with an amniotic membrane graft that improved the visual acuity and gave a marked reduction in symptoms for 6 months, but further follow-up is required to confirm the duration of this effect.
Although most reports of GDLD are from East Asia, cases have also been reported from other regions. 5 To date, 28 different disease-causing mutations in the TACSTD2 gene have been reported. The majority of mutations are predicted to produce truncated proteins, or proteins degraded by nonsense mediated decay, because of nucleotide substitutions that generate premature stop codons. The remainder are missense changes of conserved residues. The most frequently reported mutation is the c.352C.T, p.(Q118X) mutation, which is a founder mutation in the Japanese population, explaining the higher prevalence of GDLD in Japan. 14 Figure 3 shows a schematic representation of pathogenic TACSTD2 mutations, including the p.(Y184C) mutation, and their location in regards to the functional domains of the TACSTD2 protein. Given the range of previously described missense mutations, it is noteworthy that cysteine residues are often eliminated or created, which might point to a common mechanism of disruption of disulfide bonds in the extracellular domain of the protein. In the cornea, TACSTD2 is localized to epithelial cell junctions, and reduction of TACSTD2 expression has been shown to lead to altered expression and modification of intercellular proteins, including claudins 1, 4, and 7, ZO1, and occludin. 15 This impairs the function of the epithelial barrier, allowing the formation of amyloid deposits of lactoferrin, apolipoprotein, and transforming growth factor b. [23] [24] [25] [26] There is evidence that amyloid fibers are formed by nonenzymatic posttranslational modifications of these proteins, including the formation of advanced glycation end products and the racemization of aspartyl residues that lead to the misfolding of DNA, resistance to degradation, and posterior accumulation. 25 A single heterozygous carrier of the p.(Y184C) mutation was identified in the 1000 Genomes Project, which includes exome sequence data for 93 unrelated individuals from Colombia, suggesting a 0.53% frequency for the allele in this population. Based on this allele frequency, and excluding inbreeding, we estimated the prevalence of GDLD to be 1:35,714 in Colombia, which is 8.5 times the prevalence of GDLD in the Japanese population, for which a founder effect for the p.(Q118X) mutation has been reported. The family is originally from a village in the Department of Caldas in Colombia that has had a rapid expansion in population since its founding. 26 This is the first clinical, genetic, and histopathological description of GDLD from Colombia. The clinical variability of the corneal changes in the affected family members helps define the phenotype of this disease. The most severely affected individual (II:5; 23 years of age) had a history of a colon adenocarcinoma. Although this association has not been highlighted in other reports, a higher expression of TACSTD2 has been reported to be associated with aggressive colorectal carcinoma. 27 It is noteworthy that the relatively high frequency of this allele in ethnically matched control subjects predicts a higher frequency of the disease in Colombia than has been reported in the Japanese population.
